Navigation Links
Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
Date:4/17/2010

MM-121 studies in breast cancer models and xenograft response prediction. MM-111 breast cancer study in combination with trastuzumab.

Cambridge, MA (PRWEB) April 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.

MM-121
Two posters will show pre-clinical data on MM-121, a monoclonal antibody designed to block signaling of the ErbB3 receptor. The ErbB receptor family has been known for years to have an impact on cancer signaling. Merrimack gained insight into the critical role of the ErbB3 receptor in cancer biology through the use of their Network Biology platform that led to the novel design of MM-121.

Poster 1806 shows pre-clinical data on MM-121’s efficacy as a single agent, and in combination with tamoxifen and paclitaxel, in ER+ and triple negative breast cancer studies.

Title: Efficacy of MM-121 in ER+ and triple negative breast cancer studies
Poster Session: Clinical Research 7
Number: 1806
Date/Time: Monday April 19, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 32 Permanent Abstract


MM-121
Poster 3756 shows pre-clinical data on efforts to derive a predictive biomarker signature that identifies tumors responsive to MM-121.

Title: Prediction of xenograft response to MM-121, an anti-ErbB3 inhibitor, using computational modeling and measurements of five biomarkers
Poster Session: Clinical Research 13
Number: 3756
Date/Time: Tuesday April 20, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 33


MM-111
MM-111 is a bispecific antibody designed to specifically inhibit ErbB3 signaling in ErbB2-overexpressing cancer cells. MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it from activating pAKT, an important mediator of cancer cell survival.

Poster 3485 shows pre-clinical data on the potent combinatorial effect of MM-111 and trastuzumab on inhibiting tumor cell growth driven by the ErbB2/3 signaling network

Title: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit
Poster Session: Experimental and Molecular Therapeutics 22
Number: 3485
Date/Time: Tuesday April 20, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 21 Permanent Abstract

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:    Kathleen Petrozzelli, Corporate Communications, Merrimack, 617-441-1043
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424

# # #

Read the full story at http://www.prweb.com/releases/2010/04/prweb3888544.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
2. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
3. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
4. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
5. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
6. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
7. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):